Johns W D, Garnick M B, Kaplan W D
Department of Radiology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Clin Nucl Med. 1990 Jul;15(7):485-7. doi: 10.1097/00003072-199007000-00006.
The scintigraphic "flare" phenomenon on bone imaging refers to an increase in intensity of tracer uptake in sites of bone metastases and/or the appearance of "new" lesions, which occur shortly after commencement of hormonal therapy or chemotherapy for breast, prostate, or lung cancer. In this study, we observed that scintigraphic flare can occur in patients with prostate cancer following treatment with the "hormone-like" luteinizing hormone releasing hormone analog, leuprolide acetate. Twenty-six patients with prostate cancer being treated with leuprolide acetate underwent serial bone scans at three-month intervals. Five (19.2%) of the 26 patients had findings consistent with a scintigraphic flare on bone scans obtained between three and six months after initiation of therapy. These scan findings should not be confused with progression of skeletal metastases.
骨显像中的闪烁“耀斑”现象是指在乳腺癌、前列腺癌或肺癌的激素治疗或化疗开始后不久，骨转移部位的示踪剂摄取强度增加和/或出现“新”病变。在本研究中，我们观察到，用“激素样”促黄体激素释放激素类似物醋酸亮丙瑞林治疗的前列腺癌患者可出现骨闪烁耀斑。26例接受醋酸亮丙瑞林治疗的前列腺癌患者每隔3个月进行一次系列骨扫描。26例患者中有5例（19.2%）在治疗开始后3至6个月期间进行的骨扫描结果与骨闪烁耀斑相符。这些扫描结果不应与骨转移的进展相混淆。
